564
Views
20
CrossRef citations to date
0
Altmetric
Systematic Review

The efficacy and safety of low-dose rituximab in immune thrombocytopenia: a systematic review and meta-analysis

, , , , , & show all
Pages 690-697 | Received 24 Jan 2019, Accepted 16 Apr 2019, Published online: 03 Jun 2019

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (3)

David Gómez-Almaguer, Edgar A. Rojas-Guerrero, Andrés Gómez-De León, Perla R. Colunga-Pedraza & José C. Jaime-Pérez. (2022) Alternatives for managing patients with newly diagnosed immune thrombocytopenia: a narrative review. Expert Review of Hematology 15:6, pages 493-501.
Read now
Melanie Sandvad, Emilie Arntoft Pedersen, Henrik Frederiksen & Nikolaj Mannering. (2021) Risk of infection in adult patients with primary immune thrombocytopenia (ITP): a systematic review. Expert Review of Hematology 14:10, pages 961-974.
Read now
Yan-ming Wang, Ya-fei Yu, Yu Liu, Shuang Liu, Ming Hou & Xin-guang Liu. (2020) The association between antinuclear antibody and response to rituximab treatment in adult patients with primary immune thrombocytopenia. Hematology 25:1, pages 139-144.
Read now

Articles from other publishers (17)

Dae Sik Kim. (2022) Recent advances in treatments of adult immune thrombocytopenia. Blood Research 57:S1, pages S112-S119.
Crossref
Marina Beltrami‐Moreira & James B. Bussel. (2022) Low‐dose rituximab in immune thrombocytopenia: One and done. American Journal of Hematology 97:4, pages 388-389.
Crossref
Xiaofei Ni, Daqi Li, Chenglu Yuan, Yafei Yu, Haoyi Wang, Lingjun Wang, Tianshu Yu, Ping Qin, Jun Peng, Ming Hou, Yan Shi & Yu Hou. (2022) Single‐dose versus low‐dose rituximab in corticosteroid‐resistant or relapsed ITP : A multicenter, randomized, controlled study . American Journal of Hematology 97:4, pages 440-447.
Crossref
Juan Camilo Santacruz, Marta Juliana Mantilla, Igor Rueda, Sandra Pulido, Gustavo Rodriguez-Salas & John Londono. (2022) A Practical Perspective of the Hematologic Manifestations of Systemic Lupus Erythematosus. Cureus.
Crossref
Ye-Jun WuHui LiuQiao-Zhu ZengYi LiuJing-Wen WangWen-Sheng Wang Jia-Feng, He-Bing Zhou, Qiu-Sha HuangYun HeHai-Xia FuXiao-Lu ZhuQian JiangHao JiangYing-Jun ChangLan-Ping XuXiao-Jun Huang & Xiao-Hui Zhang. (2022) All- trans retinoic acid plus low-dose rituximab vs low-dose rituximab in corticosteroid-resistant or relapsed ITP . Blood 139:3, pages 333-342.
Crossref
Chenjia He, Wenyu Li, Qibing Xie & Geng Yin. (2022) Rituximab in the Treatment of Interstitial Lung Diseases Related to Anti-Melanoma Differentiation-Associated Gene 5 Dermatomyositis: A Systematic Review. Frontiers in Immunology 12.
Crossref
Philip YI Choi, Eileen Merriman, Ashwini Bennett, Anoop K Enjeti, Chee Wee Tan, Isaac Goncalves, Danny Hsu & Robert Bird. (2021) Consensus guidelines for the management of adult immune thrombocytopenia in Australia and New Zealand. Medical Journal of Australia 216:1, pages 43-52.
Crossref
Stewart Hunt, Jeremy Robertson, Jason Conn, John Casey, Jane Royle, Joel Collins, Matthew Hourigan, Joshua Richmond, Tzu Yang Wang, Anthony Mills & Jane Mason. (2021) A low‐dose rituximab regimen for first‐line treatment of acquired haemophilia A. European Journal of Haematology 108:1, pages 28-33.
Crossref
Yu Dong, Ming Yue & Mengjiao Hu. (2021) The Efficacy and Safety of Different Dosages of Rituximab for Adults with Immune Thrombocytopenia: A Systematic Review and Meta-Analysis. BioMed Research International 2021, pages 1-13.
Crossref
María L. Lozano, Miguel A. Sanz & Vicente Vicente. (2021) Recomendaciones del Grupo Español de PTI para el diagnóstico, tratamiento y seguimiento de pacientes con trombocitopenia inmune. Medicina Clínica 157:4, pages 191-198.
Crossref
María L. Lozano, Miguel A. Sanz & Vicente Vicente. (2021) Guidelines of the Spanish ITP Group for the diagnosis, treatment and follow-up of patients with immune thrombocytopenia. Medicina Clínica (English Edition) 157:4, pages 191-198.
Crossref
Kundan Mishra, Suman Kumar, Aditya Jandial, Kamal Kant Sahu, Rajeev Sandal, Ankur Ahuja, Sanjeev Khera, Yanamandra Uday, Rajiv Kumar, Rajan Kapoor, Tarun Verma, Sanjeevan Sharma, Jasjit Singh, Satyaranjan Das, Tathagat Chatterjee, Ajay Sharma & Velu Nair. (2021) Real-world Experience of Rituximab in Immune Thrombocytopenia. Indian Journal of Hematology and Blood Transfusion 37:3, pages 404-413.
Crossref
Yongpeng Ge, Shanshan Li, Xiaolan Tian, Linrong He, Xin Lu & Guochun Wang. (2021) Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis responds to rituximab therapy. Clinical Rheumatology 40:6, pages 2311-2317.
Crossref
Anurag Singh, Günalp Uzun & Tamam Bakchoul. (2021) Primary Immune Thrombocytopenia: Novel Insights into Pathophysiology and Disease Management. Journal of Clinical Medicine 10:4, pages 789.
Crossref
Wanlu Ma, Wei BaiXueyan Wu, Jiuliang Zhao, Mengtao Li & Xiaofeng Zeng. (2020) Successful treatment of refractory thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus with combination of plasma exchange and low-dose rituximab. Lupus 29:14, pages 1961-1967.
Crossref
Nikola Pantić & Nada Suvajdžić-Vuković. (2020) Treating ITP: What are the options in the era of new guidelines and new drugs?. Medicinski podmladak 71:4, pages 40-46.
Crossref
Melissa J. Rose & Amanda Jacobson-Kelly. 2020. Pediatric Bleeding Disorders. Pediatric Bleeding Disorders 151 160 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.